Exactech Announces Successful First Surgeries Using InterSep™ Calcium Sulfate Bone Void Filler

No comments

View All Recently Published Orthopedic Reports by iData Research

Exactech, an innovator and manufacturer in the bone and joint restoration products segment has announced the successful first surgery using its recently launched InterSepTM calcium sulfate bone void filler. InterSep is a synthetic bone void filler made from synthetic calcium sulfate, which has been engineered to fully resorb and replace bone during the body’s healing process. InterSep may be used in a variety of bone and joint replacement surgeries, including infected bone sites, providing surgeons flexibility with its bead and paste options.

Orthopaedic surgeons Mark Brandon, M.D., from the Richmond University Medical Center in Staten Island, NY, and Timothy van de Leur, M.D., of The Orthopaedic Institute, Ocala, Fla., performed the first cases using InterSep and reported superior results.

According to extensive research conducted by iData Research, the total market for bone graft substitutes, which included allografts, demineralized bone matricies (DBM) and synthetic grafts, have a market value of over $1 billion. The synthetic bone grafts accounted for the largest portion of the market followed by the DBM grafts. Market growth has been supported by the strong adoption of the BMP growth factor market, which is represented by Medtronic’s INFUSE® product. Furthermore, the rapidly growing cellular allograft market has benefited the bone graft substitute market by allowing greater osteogenic properties with the use of stem cells. The recent resurgence of growth in the more inexpensive allograft material market has driven DBM prices lower in order to stay competitive. The synthetic bone graft segment surpassed the DBM segment, due to both a higher ASP and stronger unit sales growth in the U.S. market. Synthetic grafts are more commonly used in spinal surgeries instead of applications involving larger volumes, as with fracture repair. These large volume indications are the reason that more inexpensive options, such as allograft bone, play an important role in the market. Seeing as Exactech’s InterSepTM is synthetic, it should be received by the bone graft substitute market well.

Van de Leur, a revision total joint specialist, is inspired that Exactech continues to support surgeons with innovative and relevant solutions. “InterSep was fast and easy to use with its flexible putty or bead options. InterSep will help to reassure me when patients present greater risk or are already dealing with infection.” InterSep, manufactured by Pacific Bioceramics, is currently available at select hospitals and surgery centers throughout the U.S. with plans for a full launch during the second half of this year.


For Further Information

More on the orthopedic biomaterials market in the U.S., South Korea, India, China, 15 countries in Europe and Japan can be found in a series of reports published by iData Research entitled the Market Suite for Orthopedic Biomaterials.

iData ResearchExactech Announces Successful First Surgeries Using InterSep™ Calcium Sulfate Bone Void Filler